Mirum Pharmaceuticals, Inc. (MIRM)
Nasdaq · Healthcare · Biotechnology
$81.43−1.81%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $5.3B
- 52-week range
- $63.23 – $130.00
- 52-week change
- +14.34%
- EPS (trailing)
- −$14.10
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $521M (+54.74%)
- Net income
- −$23.4M
- Operating margin
- −4.2%
- Diluted EPS
- −$0.47
- Free cash flow
- $54.9M
From the company’s annual report on SEC EDGAR.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis.
Headquarters: Foster City, United States · 433 employees · mirumpharma.com